Background Azvudine has clinical benefits and acceptable safety against COVID-19,
including in patients with comorbidities, but there is a lack of available data for its use in …

Azvudine is recommended by Chinese health authorities for COVID‐19 treatment but has
not been tested in real‐world clinical studies. This study aimed to evaluate the real‐world …

Background As the COVID-19 pandemic continues to spread, the number of associated
deaths continues to increase, especially among those with pre-existing conditions. Azvudine …

Objective The aim of this study was to assess the effectiveness and safety of azvudine in
treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory …

Background Since the end of 2022, Azvudine was widely used to treat hospitalized novel
coronavirus disease 2019 (COVID-19) patients in China. However, data on the clinical …

Abstract Coronavirus disease 2019 (COVID‐19) has spread worldwide. To date, no specific
drug for COVID‐19 has been developed. Thus, this randomized, open‐label, controlled …

Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …

Current guidelines prioritize the use of the Azvudine in coronavirus disease 2019 (COVID-
19) patients. However, the clinical effectiveness of Azvudine in real-world studies was …

Introduction Azivudine has undergone a few randomized controlled trials (RCTs) as of late.
This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety …

This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir,
and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort …